{"product_id":"live-biotherapeutic-products-and-microbiome-manufacturing-market-2nd-edition-2022-2035","title":"Live Biotherapeutic Products and Microbiome Manufacturing Market (2nd Edition), 2022-2035","description":"\u003cp\u003eLive Biotherapeutic Products and Microbiome Manufacturing Market (2nd Edition), 2022-2035\u003c\/p\u003e\n\n\u003cp\u003eGiven the advancement of several promising microbiome-based live biotherapeutic products through clinical pipeline, this upcoming therapeutic segment is anticipated to become one of the fastest growing markets within the pharmaceutical industry in the coming years.  Specifically, in 2020, around 575 IND applications were filed for such therapies, targeting a myriad of diseases indications, including autoimmune, gastrointestinal, infectious, metabolic and oncological disorders, indicating remarkable scientific progress of these breakthrough drug candidates. It is also worth highlighting that SER-109, a microbiome-based therapy developed by Seres Therapeutics, is expected to receive marketing approval from the US Food and Drug Administration (FDA) in 2022; this is further likely to propel the growth in this domain.  Further, over 640 patents focused on microbiome therapeutics were granted approval in the year 2020. In addition, during the same time frame, USD 1.5 billion was invested for the development of microbiome-based therapeutics.  Although a lot has been achieved in terms of development of live biotherapeutic products, there are certain challenges associated with the complexity of the process. Other key concerns shared by contemporary innovators include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP) and capacity. ,\u003c\/p\u003e \n\n\u003cp\u003eIn order to address the technical and operational challenges outlined above, several microbiome developers prefer to rely on contract manufacturing organizations (CMOs). It is worth highlighting that, currently, over 50 players engaged in the manufacturing of microbiome-related products carry out operations either in-house or on contract basis. The current market landscape of microbiome contract manufacturers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. Moreover, in recent years, several players engaged in this domain have forged strategic alliances and \/ or acquired other players, in order to further enhance their respective service offerings and operate as one-stop-shops. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the microbiome production process, we believe that the microbiome manufacturing market is expected to witness significant growth over the next decade.\u003c\/p\u003e\n\n\u003cp\u003eSCOPE OF THE REPORT\u003c\/p\u003e\n\n\u003cp\u003eThe “Live Biotherapeutic Products and Microbiome Manufacturing Market by Type of Product Manufactured (API and FDF), Type of Formulation (Solids, Oral Liquids and Injectables), Type of Primary Packaging Used (Blister Packs, Glass \/ Plastic Bottles, Pouches \/ Sachets and Vials), Scale of Operation (Clinical and Commercial), Company Size (Small, Mid-sized and Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022 – 2035” report features an extensive study on the in- house and contract manufacturing organizations within the microbiome industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:\u003cbr\u003e\nA detailed overview of the overall landscape of companies offering contract manufacturing services for the development of microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media \/ culture development, fermentation, lyophilization, fill \/ finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass \/ plastic bottles, pouches \/ sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. Further, it provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities. \u003cbr\u003e\nA detailed landscape of the live biotherapeutic products and microbiome manufacturing facilities established across key geographical regions (North America, Europe and Asia-Pacific), highlighting the key manufacturing hubs for microbiomes.  \u003cbr\u003e\nAn in-depth company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (in terms of scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.\u003cbr\u003e\nElaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics across both clinical and commercial scales of operation. Each profile features a brief overview of the company, details related to its microbiome-related service portfolio, microbiome manufacturing facilities, recent developments, and an informed future outlook.\u003cbr\u003e\nA list of nearly 70 microbiome-focused drug developers that are likely to partner with manufacturers engaged in this domain. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.\u003cbr\u003e\nA review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.\u003cbr\u003e\nAn analysis of recent developments within the microbiome manufacturing industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.\u003cbr\u003e\nAn in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions. \u003cbr\u003e\nAn estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity based on the scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).\u003cbr\u003e\nAn informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.\u003cbr\u003e\nA qualitative analysis, highlighting various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.\u003cbr\u003e\nA case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on their year of establishment, company size and location of headquarters.\u003c\/p\u003e\n\n\u003cp\u003eOne of the key objectives of the report was to evaluate the current opportunity and the future potential of the microbiome manufacturing market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass \/ plastic bottles, pouches \/ sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.\u003c\/p\u003e\n\n\u003cp\u003eAll actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.\u003c\/p\u003e\n\n\u003cp\u003eRESEARCH METHODOLOGY\u003cbr\u003e\nThe data presented in this report has been gathered via secondary and primary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.\u003c\/p\u003e\n\n\u003cp\u003eThe secondary sources of information include: \u003cbr\u003e\nAnnual reports\u003cbr\u003e\nInvestor presentations\u003cbr\u003e\nSEC filings\u003cbr\u003e\nIndustry databases\u003cbr\u003e\nNews releases from company websites\u003cbr\u003e\nGovernment policy documents\u003cbr\u003e\nIndustry analysts’ views\u003c\/p\u003e\n\n\u003cp\u003eWhile the focus has been on forecasting the market till 2035, the report also provides our independent view on technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.\u003c\/p\u003e \n\n\u003cp\u003eKEY QUESTIONS ANSWERED\u003cbr\u003e\nWho are the key players engaged in offering contract manufacturing services for microbiome therapeutics?\u003cbr\u003e\nWhat are the key challenges faced by microbiome contract manufacturers?\u003cbr\u003e\nWho are the most likely partners (microbiome-based live biotherapeutic drug developers) for microbiome contract manufacturers?\u003cbr\u003e\nWhat is the annual clinical demand for microbiome-based live biotherapeutics? \u003cbr\u003e\nWhat is the current, installed contract manufacturing capacity for live biotherapeutics?\u003cbr\u003e\nWhat are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision in this field?\u003cbr\u003e\nWhat are the various initiatives undertaken by big pharma players in this domain? \u003cbr\u003e\nWhat percentage of live biotherapeutics manufacturing operations are outsourced to service providers?\u003cbr\u003e\nHow is the current and future market opportunity likely to be distributed across key market segments?\u003cbr\u003e\nWhat are the anticipated future trends related to live biotherapeutics manufacturing?\u003c\/p\u003e\n\n\u003cp\u003eCHAPTER OUTLINES\u003cbr\u003e\nChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the microbiome therapeutics manufacturing market and its likely evolution in the short-mid term and long term.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a general introduction to the human microbiome, along with information on the various types of microbiome therapeutics. It also features an elaborate discussion on the functions of the microbiota, emphasizing on the key insights generated from the human microbiome project (HMP). Further, the chapter features the various steps that are involved in the manufacturing of microbiome therapeutics. In addition, it highlights the challenges associated with manufacturing such products and the growing need for outsourcing in this domain. Finally, it provides a list of key factors that need to be considered by innovator companies while selecting a CMO partner.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides an overview of the microbiome contract manufacturing landscape. It includes information on over 25 contract manufacturers that claim to offer microbiome therapeutics manufacturing services. In addition, it features an in-depth analysis of these companies, based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media \/ culture development, fermentation, lyophilization, fill \/ finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of fermentation (aerobic and anaerobic), type of formulation (solids, oral liquids and injectables), type of primary packaging used (blister packs, glass \/ plastic bottles, pouches \/ sachets, and vials), number and location of manufacturing facilities and bioprocessing capacity. It also provides a list of companies with in-house manufacturing facilities for microbiome therapeutics, along with information on their year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities.\u003c\/p\u003e \n\n\u003cp\u003eChapter 5 provides a detailed landscape of microbiome manufacturing facilities in key regions (North America, Europe and Asia-Pacific). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 features an insightful company competitiveness analysis of microbiome manufacturing service providers based on their product portfolio strength (scale of operation, type of product manufactured, type of formulation, type of primary packaging used and number of manufacturing facilities), service strength (based on its experience) and type of service(s) offered.\u003c\/p\u003e\n\n\u003cp\u003eChapter 7 includes detailed profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome-based live biotherapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities, and recent developments and an informed future outlook.\u003c\/p\u003e\n\n\u003cp\u003eChapter 8 provides list of nearly 70 microbiome-focused drug developers that are anticipated to partner with manufacturers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of in-house manufacturing capabilities.\u003c\/p\u003e\n\n\u003cp\u003eChapter 9 presents a review of the various microbiome-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2021), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome-focused entities), along with information on funding, partnership activity,  and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation, comparing the initiatives of big pharma players on the basis of multiple relevant parameters.\u003c\/p\u003e\n\n\u003cp\u003eChapter 10 presents detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the microbiome manufacturing industry, during the period between 2016 and 2021.\u003c\/p\u003e\n\n\u003cp\u003eChapter 11 features an in-depth analysis of completed, ongoing, and planned clinical studies of various microbiome therapeutics, based on several relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target disease indication and key geographical regions.\u003c\/p\u003e \n\n\u003cp\u003eChapter 12 provides an estimate of the overall, installed capacity for the manufacturing of microbiome-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).\u003c\/p\u003e\n\n\u003cp\u003eChapter 13 presents an informed estimate of the annual clinical and commercial demand for microbiome therapeutics, taking into account the target patient population in ongoing and planned clinical trials of microbiome therapeutics, sponsored by both industry and non-industry players.\u003c\/p\u003e\n\n\u003cp\u003eChapter 14 provides a qualitative analysis, highlighting the various factors that need to be taken into consideration by microbiome therapeutics developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.\u003c\/p\u003e\n\n\u003cp\u003eChapter 15 includes a case study on the current market landscape of microbiome contract research organizations and dietary supplement providers, including information on the year of establishment, company size and location of headquarters.\u003c\/p\u003e\n\n\u003cp\u003eChapter 16 presents an insightful market forecast analysis, highlighting the future potential of microbiome manufacturing market till 2035. We have segmented the market on the basis of [A] type of product manufactured (API and FDF), [B] type of formulation (solids, oral liquids and injectables), [C] type of primary packaging used (blister packs, glass \/ plastic bottles, pouches \/ sachets and vials) [D] scale of operation (clinical and commercial), [E] company size (small, mid-sized and large) and [F] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).\u003c\/p\u003e\n\n\u003cp\u003eChapter 17 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the microbiome contract manufacturing market, based on the research and analysis described in the previous chapters. \u003cbr\u003e\nChapter 18 is a collection of transcripts of interviews conducted with various stakeholders in the industry.\u003c\/p\u003e \n\n\u003cp\u003eChapter 19 is an appendix that contains tabulated data and numbers for all the figures provided in the report.\u003c\/p\u003e\n\n\u003cp\u003eChapter 20 is an appendix that provides the list of companies and organizations mentioned in the report.\u003c\/p\u003e\n\n\u003cp\u003eLIST OF COMPANIES AND ORGANIZATIONS\u003cbr\u003e\nThe following companies \/ institutes \/ government bodies and organizations have been mentioned in this report.\u003c\/p\u003e\n\n\u003cp\u003e1.\t4D Pharma\u003cbr\u003e\n2.\tAbbVie\u003cbr\u003e\n3.\tABCO Laboratories\u003cbr\u003e\n4.\tABH Pharma\u003cbr\u003e\n5.\tAdare Pharmaceuticals\u003cbr\u003e\n6.\tADM Biopolis\u003cbr\u003e\n7.\tAdvanced Enzymes\u003cbr\u003e\n8.\tAllianz Biosciences \u003cbr\u003e\n9.\tAmpliPhi Biosciences\u003cbr\u003e\n10.\tAOBiome Therapeutics\u003cbr\u003e\n11.\tArena Pharmaceuticals\u003cbr\u003e\n12.\tArmata Pharmaceuticals\u003cbr\u003e\n13.\tArranta Bio\u003cbr\u003e\n14.\tAsiaBiome \u003cbr\u003e\n15.\tAssembly Biosciences\u003cbr\u003e\n16.\tAstraZeneca\u003cbr\u003e\n17.\tAtlantic Essential Products\u003cbr\u003e\n18.\tAumgene Biosciences\u003cbr\u003e\n19.\tAxial Therapeutics\u003cbr\u003e\n20.\tAzabu University\u003cbr\u003e\n21.\tAzitra\u003cbr\u003e\n22.\tBacThera\u003cbr\u003e\n23.\tBiena\u003cbr\u003e\n24.\tBifodan \u003cbr\u003e\n25.\tBIOASTER\u003cbr\u003e\n26.\tBioCare\u003cbr\u003e\n27.\tBiocodex\u003cbr\u003e\n28.\tBioGaia\u003cbr\u003e\n29.\tBiomar Microbial Technologies\u003cbr\u003e\n30.\tBiomcare\u003cbr\u003e\n31.\tBio-Me\u003cbr\u003e\n32.\tBiomica (a subsidary of Evogene)\u003cbr\u003e\n33.\tBiomillenia\u003cbr\u003e\n34.\tBiomX\u003cbr\u003e\n35.\tBiose\u003cbr\u003e\n36.\tBiosortia Pharmaceuticals\u003cbr\u003e\n37.\tBJP Laboratories\u003cbr\u003e\n38.\tBloom Science\u003cbr\u003e\n39.\tBlue Turtle Bio\u003cbr\u003e\n40.\tBoehringer Ingelheim\u003cbr\u003e\n41.\tBristol-Myers Squibb\u003cbr\u003e\n42.\tC3J Therapeutics\u003cbr\u003e\n43.\tCaelus Health\u003cbr\u003e\n44.\tCambridge University Hospitals NHS Foundation Trust\u003cbr\u003e\n45.\tCancer Research UK\u003cbr\u003e\n46.\tCapsugel\u003cbr\u003e\n47.\tCaptozyme\u003cbr\u003e\n48.\tCell Biotech\u003cbr\u003e\n49.\tCerbios-Pharma\u003cbr\u003e\n50.\tCHAIN Biotechnology\u003cbr\u003e\n51.\tCharles River Laboratories\u003cbr\u003e\n52.\tChr. Hansen\u003cbr\u003e\n53.\tClinical Microbiomics\u003cbr\u003e\n54.\tClostraBio\u003cbr\u003e\n55.\tCommense (a subsidiary of PureTech Health)\u003cbr\u003e\n56.\tCoreBiome\u003cbr\u003e\n57.\tCosmosID\u003cbr\u003e\n58.\tCrestovo\u003cbr\u003e\n59.\tCustom Probiotics\u003cbr\u003e\n60.\tDa Volterra\u003cbr\u003e\n61.\tDebiopharm\u003cbr\u003e\n62.\tDeerland Probiotics \u0026amp; Enzymes\u003cbr\u003e\n63.\tDermBiont\u003cbr\u003e\n64.\tDiversigen \u003cbr\u003e\n65.\tDuPont\u003cbr\u003e\n66.\tEirGenix\u003cbr\u003e\n67.\tEmerge Health\u003cbr\u003e\n68.\tEMF\u003cbr\u003e\n69.\tEmulate\u003cbr\u003e\n70.\tEnterin\u003cbr\u003e\n71.\tEnteroBiotix\u003cbr\u003e\n72.\tEnterome\u003cbr\u003e\n73.\tEvelo Biosciences\u003cbr\u003e\n74.\tEvologic Technologies\u003cbr\u003e\n75.\tEXDEN\u003cbr\u003e\n76.\tExeliom Biosciences\u003cbr\u003e\n77.\tExim Pharma\u003cbr\u003e\n78.\tFerring Pharmaceuticals\u003cbr\u003e\n79.\tFinch Therapeutics\u003cbr\u003e\n80.\tFUJIFILM Diosynth Biotechnologies\u003cbr\u003e\n81.\tGaneden Biotech\u003cbr\u003e\n82.\tGENIBIO (a subsidiary of the LARENA and GB ACTION)\u003cbr\u003e\n83.\tGenome \u0026amp; Company\u003cbr\u003e\n84.\tGI Innovation\u003cbr\u003e\n85.\tGilead Sciences\u003cbr\u003e\n86.\tGinkgo Bioworks\u003cbr\u003e\n87.\tGustave Roussy\u003cbr\u003e\n88.\tGusto Global\u003cbr\u003e\n89.\tHeidelberg University\u003cbr\u003e\n90.\tiCarbonX\u003cbr\u003e\n91.\tIgen BioLab Group\u003cbr\u003e\n92.\tImmuneBiotech\u003cbr\u003e\n93.\tImmuron\u003cbr\u003e\n94.\tInfant Bacterial Therapeutics\u003cbr\u003e\n95.\tInpac Probiotics \u003cbr\u003e\n96.\tIon Labs\u003cbr\u003e\n97.\tJeneil Biotech\u003cbr\u003e\n98.\tJohn Theurer Cancer Center\u003cbr\u003e\n99.\tJohnson \u0026amp; Johnson\u003cbr\u003e\n100.\tJW Nutritional\u003cbr\u003e\n101.\t Kaleido Biosciences\u003cbr\u003e\n102.\t Karolinska Institutet\u003cbr\u003e\n103.\t Karyotica Biologicals\u003cbr\u003e\n104.\t Kendy Pharma\u003cbr\u003e\n105.\t Kibow Biotech\u003cbr\u003e\n106.\t Lallemand \u003cbr\u003e\n107.\t Leadiant Biosciences\u003cbr\u003e\n108.\t Leiden University Medical Center\u003cbr\u003e\n109.\t List Biological Laboratories\u003cbr\u003e\n110.\t LNC Therapeutics\u003cbr\u003e\n111.\t Locus Biosciences\u003cbr\u003e\n112.\t Lonza\u003cbr\u003e\n113.\t LUCA Biologics\u003cbr\u003e\n114.\t Luina Bio\u003cbr\u003e\n115.\t MaaT Pharma\u003cbr\u003e\n116.\t Massachusetts General Hospital\u003cbr\u003e\n117.\t MatriSys Bioscience\u003cbr\u003e\n118.\t Mayo Clinic\u003cbr\u003e\n119.\t Medella Naturals\u003cbr\u003e\n120.\t Memorial Sloan Kettering Cancer Center \u003cbr\u003e\n121.\t Merck\u003cbr\u003e\n122.\t MeriCal\u003cbr\u003e\n123.\t MetaboGen\u003cbr\u003e\n124.\t Meteoric Biopharmaceuticals\u003cbr\u003e\n125.\t Microba Life Sciences\u003cbr\u003e\n126.\t Microbax\u003cbr\u003e\n127.\t Microbiome Insights\u003cbr\u003e\n128.\t MicrobiomeDx\u003cbr\u003e\n129.\t Microbiotica\u003cbr\u003e\n130.\t Microviable Therapeutics\u003cbr\u003e\n131.\t Mirna Therapeutics\u003cbr\u003e\n132.\t MRM Health\u003cbr\u003e\n133.\t MSD\u003cbr\u003e\n134.\t MyBiotics\u003cbr\u003e\n135.\t Naked Biome\u003cbr\u003e\n136.\t Nestlé Health Science\u003cbr\u003e\n137.\t New Bellus \u003cbr\u003e\n138.\t Nexbiome Therapeutics\u003cbr\u003e\n139.\t NIZO\u003cbr\u003e\n140.\t Norax Supplements\u003cbr\u003e\n141.\t North Zealand University Hospital\u003cbr\u003e\n142.\t Novartis\u003cbr\u003e\n143.\t Novo Nordisk\u003cbr\u003e\n144.\t NuBiyota\u003cbr\u003e\n145.\t NutraScience Labs\u003cbr\u003e\n146.\t NYU Grossman School of Medicine\u003cbr\u003e\n147.\t Osel\u003cbr\u003e\n148.\t OxThera\u003cbr\u003e\n149.\t Parker Institute for Cancer Immunotherapy\u003cbr\u003e\n150.\t Parkinson’s Institute and Clinical Center\u003cbr\u003e\n151.\t Pfizer\u003cbr\u003e\n152.\t Phi Therapeutics\u003cbr\u003e\n153.\t Phylagen\u003cbr\u003e\n154.\t Precigen ActoBio\u003cbr\u003e\n155.\t Probi\u003cbr\u003e\n156.\t ProbioFerm\u003cbr\u003e\n157.\t Probiotical\u003cbr\u003e\n158.\t Probiotics Australia\u003cbr\u003e\n159.\t ProDigest\u003cbr\u003e\n160.\t Protexin\u003cbr\u003e\n161.\t Qu Biologics\u003cbr\u003e\n162.\t Quay Pharma\u003cbr\u003e\n163.\t Quorum Innovations\u003cbr\u003e\n164.\t Rebiotix\u003cbr\u003e\n165.\t The Research Institute of St\u003cbr\u003e\n166.\t Resphera Biosciences\u003cbr\u003e\n167.\t RIKEN\u003cbr\u003e\n168.\t Rise Therapeutics\u003cbr\u003e\n169.\t Roche\u003cbr\u003e\n170.\t RondinX\u003cbr\u003e\n171.\t Roswell Park Comprehensive Cancer Center\u003cbr\u003e\n172.\t Sabinsa\u003cbr\u003e\n173.\t Sacco\u003cbr\u003e\n174.\t S-Biomedic\u003cbr\u003e\n175.\t SciBac\u003cbr\u003e\n176.\t Scioto Biosciences\u003cbr\u003e\n177.\t Second Genome\u003cbr\u003e\n178.\t Seres Therapeutics\u003cbr\u003e\n179.\t SeylanMED\u003cbr\u003e\n180.\t SFA Therapeutics\u003cbr\u003e\n181.\t Siolta Therapeutics\u003cbr\u003e\n182.\t Sirio Pharma\u003cbr\u003e\n183.\t SNIPR Biome\u003cbr\u003e\n184.\t Specialty Enzymes \u0026amp; Probiotics\u003cbr\u003e\n185.\t Stanford Cancer Institute\u003cbr\u003e\n186.\t Stanford University School of Medicine\u003cbr\u003e\n187.\t Stellate Therapeutics\u003cbr\u003e\n188.\t Symberix\u003cbr\u003e\n189.\t Syngen Biotech\u003cbr\u003e\n190.\t Synlogic\u003cbr\u003e\n191.\t Synthetic Biologics\u003cbr\u003e\n192.\t Takeda Pharmaceutical\u003cbr\u003e\n193.\t The Medical University of Graz\u003cbr\u003e\n194.\t The University of Texas MD Anderson Cancer Center\u003cbr\u003e\n195.\t The University of Tokyo\u003cbr\u003e\n196.\t Trayer Biotherapeutics\u003cbr\u003e\n197.\t UAS Labs\u003cbr\u003e\n198.\t Unique Biotech\u003cbr\u003e\n199.\t University of Adelaide\u003cbr\u003e\n200.\t University of Nottingham\u003cbr\u003e\n201.\t University of Oxford\u003cbr\u003e\n202.\t University of Pennsylvania\u003cbr\u003e\n203.\t University of Reading\u003cbr\u003e\n204.\t Vaiomer\u003cbr\u003e\n205.\t Vedanta Biosciences\u003cbr\u003e\n206.\t VITA-gen Laboratories\u003cbr\u003e\n207.\t Vitakem\u003cbr\u003e\n208.\t Wacker Biotech\u003cbr\u003e\n209.\t Washington University School of Medicine\u003cbr\u003e\n210.\t White Rock Capital Partners\u003cbr\u003e\n211.\t Winclove Probiotics\u003cbr\u003e\n212.\t Xycrobe Therapeutics (a subsidiary of Crown Laboratories)\u003cbr\u003e\n213.\t Yakult Honsha\u003cbr\u003e\n214.\t Zeta Farmaceutici\u003c\/p\u003e\n\n\u003cp\u003ePlease note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"August, 2023 \/ 305 Pages \/ MCW16231510","offer_id":47647321882930,"sku":null,"price":5759.0,"currency_code":"USD","in_stock":true},{"title":"August, 2023 \/ 305 Pages \/ MCW16231511","offer_id":47647321915698,"sku":null,"price":5759.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/live-biotherapeutic-products-and-microbiome-manufacturing-market-2nd-edition-2022-2035","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}